Professor Tim Lambert

Professor of Psychiatry
Psychiatry, Concord Clinical School

Telephone +61 2 9351 0721 (mon & fri); 9767 7161 (tues-thurs)
Fax +61 2 97677107

Map

Biographical details

Tim Lambert, BSc, MBBS, PhD, FRANZCP, is Professor of Psychiatry at Concord Clinical School at The University of Sydney in Australia. He also holds an appointment as Head of Schizophrenia Treatment and Outcomes Research at the Brain & Mind Research Institute in Sydney. In addition, he fulfils clinical duties for Sydney Local Health Network as Director of the Centre of Excellence in Relapse Prevention in Psychosis (CERP), and at the Concord Centre for Cardiometabolic Health in Psychosis (ccCHiP).

Professor Lambert has a portfolio of interests in translational aspects of clinical neuropharmacology and neurosciences. These span clinical psychosis research, outcomes research, service delivery models, training, and education. His current interests focus on services research (pharmacoepidemiology, developing novel relapse prevention, treatment resistance, and cardiometabolic services for the seriously mentally ill); the clinical pharmacology of LAI antipsychotics (first and second generation) and of the second-generation antipsychotics, particularly risk-benefit aspects and the applied clinical pharmacology of antipsychotic switching; physical comorbidities of psychotic disorders, especially cardiometabolic syndromes; and incomplete recovery. Social aspects, particularly the role of acculturation on clinical phenotypes permeate all facets of these programmes. In terms of education and training, his team has been developing newmedia-based approaches to education and this work has been utilised to produce educational and training materials such as CD-ROMs, DVDs and web-based applications for mental health workers in many parts of the world. He has been a principal in the development of a number of clinical practice guidelines, algorithms, and consensus documents (Diabetes and antipsychotics; RANZCP CPG for schizophrenia; Treatment Refractory Consensus Guidelines, for example). Professor Lambert is a regularly invited lecturer, clinical trainer, and consultant throughout Asia, Australia, Europe, and North America. He is a member of a number of international and national advisory groups concerned with antipsychotic treatments and their role in community psychiatry.

Research interests

Schizophrenia

Cardiometabolic Illness in psychosis Treatment resistance Psychopharmacology of psychosis Community psychiatry Relapse Prevention Newmedia education strategies

Teaching and supervision

Undergraduate:

Schizophrenia (especially treatments, side effects); psychopathology and introduction to descriptive phenomenology; Postgraduate: All aspects of schizophrenia and related neurosciences; cross discipline approaches to improvement in psychosis outcomes

International links

Germany

(Munich Technical University) International educational collaboration for relapse prevention

United States

(Albert Einstein College of Medicine) Collaborative international education on relapse prevention as part of the CERP initiative

Selected grants

2009

  • The effects of oxytocin nasal spray on mechanisms of social-communication in young people with autism; Guastella A, Einfeld S, Reinhart N, Gray K, Lambert T, Tonge B; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Participation in the BMRI centre of Excellence: adherence and psychopharmacology of antipsychotic long-acting injections; Lambert T; Janssen-Cilag Pty Ltd/Fellowship Grant.

2007

  • Selecta Validation with CNOMSS data set; Lambert T; Janssen-Cilag Pty Ltd/Research Grant.
  • Incidence and prevalance of insulin resistance, metabolic syndrome and cardiovascular risk factors in young adults with psychotic illness; Lambert T; Bristol Myers Squibb/Research Support.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Lambert, T., Taylor, D. (2011). Pharmacology of antipsychotic long-acting injections. In Peter Haddad, Tim Lambert, John Lauriello (Eds.), Antipsychotic Long-acting injections, (pp. 23-46). Oxford, United Kingdom: Oxford University Press.
  • Lambert, T. (2011). Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspective. In Peter Haddad, Tim Lambert, John Lauriello (Eds.), Antipsychotic Long-acting injections, (pp. 209-239). Oxford, United Kingdom: Oxford University Press.
  • Haddad, P., Lambert, T., Lauriello, J. (2011). The role of antipsychotic long-acting injections in current practice. In Peter Haddad, Tim Lambert, John Lauriello (Eds.), Antipsychotic Long-acting injections, (pp. 241-260). Oxford, United Kingdom: Oxford University Press.
  • Lambert, T. (2010). Disease Management: Multidimensional Approaches to Incomplete Recovery in Psychosis. In H Elkis, H Meltzer (Eds.), Therapy-Resistant Schizophrenia, (pp. 87-113). Basel: S. Karger AG.
  • Lambert, T. (2010). Office for Psychiatric Evaluation and New Media (open). In Edmond Chiu & Joy Preston (Eds.), The Department of Psychiatry at the University of Melbourne 1964-2009: Personal Reminiscences, (pp. 130-134). Melbourne: University of Melbourne.
  • Lambert, T., Addington, J., Burnett, P. (2009). Complete and incomplete recovery from first -episode psychosis. In Patrick D McGorry, Henry J Jackson (Eds.), The Recognition and Management of Early Psychosis: A Preventive Approach, (pp. 201-222). United Kingdom: Cambridge University Press.
  • Lambert, T. (2008). Drug delivery systems in schizophrenia. In Martin Lambert, Dieter Naber (Eds.), Current Schizophrenia, (pp. 12-18). London: Current Medicine Group Ltd.
  • Lambert, T., Norman, T. (2008). Ethnic differences in psychotropic drug response and pharmacokinetics. In Chee H. Ng, Keh-Ming Lin, Bruce S. Singh, Edmond Y. K. Chiu (Eds.), Ethno-psychopharmacology: Advances in Current Practice, (pp. 38-61). United States of America: Cambridge University Press.

Journals

  • O'Connor, N., Hunt, G., O'Hara-Aarons, M., Hall, A., Snars, J., Storm, V., Lambert, T. (2014). The Sydney Mental Health Client Mortality Audit: what does it tell us and what are we to do? Australasian Psychiatry, 22(2), 154-159. [More Information]
  • Hibbert, E., Lambert, T., Carter, J., Learoyd, D., Twigg, S., Clarke, S. (2013). A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. BMC Medical Education, 13(1), 1-10. [More Information]
  • Lambert, T. (2013). Improving patient adherence in schizophrenia and schizophrenia-related disorders. International Clinical Psychopharmacology, 28(Suppl1), S1-S2. [More Information]
  • Chen, R., Lambert, T. (2013). Managing cardiovascular risk factors in people with serious mental illness: the tragedy of neglect. Endocrinology Today: peer reviewed updates for medical practitioners, 2(1), 25-27.
  • Kalucy, M., Grunstein, R., Lambert, T., Glozier, N. (2013). Obstructive sleep apnoea and schizophrenia - A research agenda. Sleep Medicine Reviews, 17(5), 357-365. [More Information]
  • Lambert, T. (2013). Practical management of schizophrenia: the role of long-acting antipsychotics. International Clinical Psychopharmacology, 28(Suppl 1), S16-S27. [More Information]
  • O'Connor, N., Mulley, R., Grasso, B., Lambert, T., Snars, J., Jhita, P. (2012). An Acute Recovery Unit: the first 18 months. Australasian Psychiatry, 20(3), 214-219. [More Information]
  • Robillard, R., Rogers, N., Whitwell, B., Lambert, T. (2012). Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review. Clinical Psychopharmacology and Neuroscience, 10(1), 1-12.
  • Feiler, G., Chen, R., Pantelis, C., Lambert, T. (2012). Health behaviours of community-treated patients with psychosis. Australasian Psychiatry, 20(3), 208-213. [More Information]
  • Lambert, T., Emmerson, B., Hustig, H., Resseler, S., Jacobs, A., Butcher, B. (2012). Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry, 12(1), 1-8. [More Information]
  • Robillard, R., Lambert, T., Rogers, N. (2012). Measuring sleep-wake patterns with physical activity and energy expenditure monitors. Biological Rhythm Research, 43(5), 555-562. [More Information]
  • Happell, B., Platania-Phung, C., Gray, R., Hardy, S., Lambert, T., McAllister, M., Davies, C. (2011). A role for mental health nursing in the physical health care of consumers with severe mental illness. Journal of Psychiatric and Mental Health Nursing, 18(8), 706-711. [More Information]
  • Lambert, T., Olivares, J., Peuskens, J., DeSouza, C., Kozma, C., Otten, P., Crivera, C., Jacobs, A., Macfadden, W., Mao, L., et al (2011). Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Annals of General Psychiatry, 10(Article number 10), 1-7. [More Information]
  • Patel, M., Matonhodze, J., Baig, M., Gilleen, J., Boydell, J., Holloway, F., Taylor, D., Szmukler, G., Lambert, T., David, A. (2011). Increased use of antipsychotic long-acting injections with community treatment orders. Therapeutic Advances in Psychopharmacology, 1(2), 37-45. [More Information]
  • Lambert, T. (2011). Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Australian Prescriber, 34(4), 97-99.
  • Dalton, A., Lambert, T., Schrover, R., Hertel, J., Kingsford Smith, D. (2011). The cost associated with administering risperidone long-acting injections in the Australian community. BMC Health Services Research, 11(236), 1-9. [More Information]
  • Kelin, K., Lambert, T., Brnabic, A., Newton, R., Ye, W., Escamilla, R., Chen, K., Don, L., Montgomery, W., Karagianis, J., et al (2011). Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence, 5, 213-222. [More Information]
  • McGorry, P., Cocks, J., Power, P., Burnett, P., Harrigan, S., Lambert, T. (2011). Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment. Schizophrenia Research and Treatment, 2011, 631690-1-631690-10. [More Information]
  • Guastella, A., Einfeld, S., Gray, K., Rinehart, N., Tonge, B., Lambert, T., Hickie, I. (2010). Intranasal Oxytocin Improves Emotion Recognition in Youth with Autism Spectrum Disorders. Biological Psychiatry, 67, 692-694. [More Information]
  • Ryder, A., Lambert, T., Blaszczynski, A. (2010). The temporal stability and the determinants of subjective well being under antipsychotic medication in first-episode psychosis. Schizophrenia Research, 117(Special Issue), 402-402. [More Information]
  • Lambert, T., Newcomer, J. (2009). Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Medical Journal of Australia, 190(4 Suppl), S39-S42. [More Information]
  • Lambert, T., Singh, B., Patel, M. (2009). Community treatment orders and antipsychotic long-acting injections. British Journal of Psychiatry, 195(52), S57-S62. [More Information]
  • Lambert, T. (2009). Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evidence-Based Mental Health, 12(2), 50. [More Information]
  • Lambert, T. (2009). The medical care of people with psychosis. Medical Journal of Australia, 190(4), 171-172. [More Information]
  • Sundram, S., Lambert, T., Piskulic, D. (2008). Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia. Acta Psychiatrica Scandinavica, 117(6), 474-478. [More Information]
  • Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C., McDonnell, D. (2008). An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia. Journal Of Clinical Psychiatry, 69(5), 790-799. [More Information]
  • Lambert, T., Detke, H., McDonnell, D., Lauriello, J., Anderson, S. (2008). Olanzapine long-acting injection: An 8-week double-blind, randomized, placebo-controlled study in acutely-ill patients with schizophrenia. International Journal of Neuropsychopharmacology, 11, 152-152.
  • Walter, G., DeLaroche, A., Soh, N., Hunt, G., Cleary, M., Malhi, G., Lambert, T., Correll, C., Rey, J. (2008). Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry, 16(4), 253-262. [More Information]
  • Iqbal, N., Lambert, T., Masand, P. (2007). Akathisia: problem of history or concern of today. CNS Spectrums, 12(Suppl 14), 9-1-9-13. [More Information]
  • Elsom, S., Happell, B., Manias, E., Lambert, T. (2007). Expanded practice roles for community mental health nurses: a qualitative exploration of psychiatrists' views. Australasian Psychiatry, 15(4), 324-328. [More Information]
  • Subramaniam, M., Ng, C., Chong, S., Mahendran, R., Lambert, T., Pek, E., Huak, C. (2007). Metabolic differences between Asian and Caucasian patients on clozapine treatment. Human Psychopharmacology-Clinical and Experimental, 22(4), 217-222. [More Information]
  • Berk, M., Fitzsimons, J., Lambert, T., Pantelis, C., Kulkarni, J., Castle, D., Ryan, E., Jespersen, S., McGorry, P., Berger, G., et al (2007). Monitoring the Safe Use of Clozapine: A Consensus View from Victoria, Australia. CNS Drugs, 21(2), 117-127. [More Information]
  • Lambert, T. (2007). Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. Journal Of Clinical Psychiatry, 68(Suppl 6), 10-13. [More Information]
  • Weiden, P., Miller, A., Lambert, T., Buckley, P. (2007). The art and science of switching antipsychotic medications, part 2. Journal of Clinical Psychiatry, 68(1), e02. [More Information]
  • Castle, D., Lambert, T., Melbourne, S., Cox, A., Boardman, G., Fairest, K., Davey, M., Goh, J., Kuluris, B., Berk, M. (2006). A clinical monitoring system for clozapine. Australasian Psychiatry, 14(2), 156-168. [More Information]
  • Lambert, T. (2006). Atypical antipsychotics in schizophrenia. Medicine Today, 7(1), 55-58.
  • Lambert, T. (2006). Selecting patients for long-acting novel antipsychotic therapy. Australasian Psychiatry, 14(1), 38-42. [More Information]
  • Fitzsimons, J., Berk, M., Lambert, T., Bourin, M., Dodd, S. (2005). A review of clozapine safety. Expert Opinion on Drug Safety, 4(4), 731-744.
  • Ng, C., Chong, S., Lambert, T., Fan, A., Hackett, L., Mahendran, R., Subramaniam, M., Schweitzer, I. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International Clinical Psychopharmacology, 20(3), 163-168. [More Information]
  • Conley, R., Kelly, D., Lambert, T., Love, R. (2005). Comparison of Clozapine Use in Maryland and in Victoria, Australia. Psychiatric Services, 56(3), 320-323. [More Information]
  • McGorry, P., Killackey, E., Lambert, T., Lambert, M., Royal Australian and New Zealand College of Psychiatrists Clinical Practice, G. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39(1-2), 1-30. [More Information]
  • Humberstone, V., Wheeler, A., Lambert, T. (2004). An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry, 38(4), 240-245.
  • Lambert, T., Chapman, L., Bell, J., Carr, N., D'Emden, M., Elsom, S., Groom, G., Henderson, S., Hickie, I., Hoffman, L., Meagher, J., et al (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Medical Journal of Australia, 181(10), 544-548.
  • Lambert, T., Kelly, D., Alcock, S., Conley, R. (2004). Letter To the Editor: Psychotropic Prescribing for Acute Inpatient Admissions in Patients with Severe Psychosis. Journal of Clinical Psychopharmacology, 24(1), 91-93.
  • Lambert, T. (2004). The value of psychiatric knowledge and expertise for general medical doctors. Emergency Psychiatry, 7, 35-38.
  • Pantelis, C., Lambert, T. (2003). Managing patients with "treatment-resistant" schizophrenia. Medical Journal of Australia, 178(9 Supplement), S62-S66.
  • Lambert, T., Cock, N., Alcock, S., Kelly, D., Conley, R. (2003). Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology-Clinical and Experimental, 18(5), 405-411. [More Information]
  • Lambert, T., Velakoulis, D., Pantelis, C. (2003). Medical comorbidity in schizophrenia. Medical Journal of Australia, 178(9 Supplement), S67-S70.
  • Gureje, O., Miles, W., Keks, N., Grainger, D., Lambert, T., McGrath, J., Tran, P., Catts, S., Fraser, A., Hustig, H., et al (2003). Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia Research, 61(2-3), 303-314.
  • Lambert, T., Brennan, A., Castle, D., Kelly, D., Conley, R. (2003). Perception of Depot Antipsychotics by Mental Health Professionals. Journal of Psychiatric Practice, 9(3), 252-260.
  • Lambert, T., Castle, D. (2003). Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia, 178(9 Supplement), S57-S61.
  • Lambert, M., Conus, P., Lambert, T., McGorry, P. (2003). Pharmacotherapy of first-episode psychosis. Expert Opinion on Pharmacotherapy, 4(5), 717-750.
  • McGorry, P., Killackey, E., Elkins, K., Lambert, M., Lambert, T. (2003). Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). Australasian Psychiatry, 11(2), 136-147.

Conferences

  • Ryder, A., Lambert, T., Blaszczynski, A. (2010). The temporal stability and the determinants of subjective well-being under antipsychotic medication in first-episode psychosis. 2nd Schizophrenia International Research Society, .: Schizophrenia International Research Society.

2014

  • O'Connor, N., Hunt, G., O'Hara-Aarons, M., Hall, A., Snars, J., Storm, V., Lambert, T. (2014). The Sydney Mental Health Client Mortality Audit: what does it tell us and what are we to do? Australasian Psychiatry, 22(2), 154-159. [More Information]

2013

  • Hibbert, E., Lambert, T., Carter, J., Learoyd, D., Twigg, S., Clarke, S. (2013). A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. BMC Medical Education, 13(1), 1-10. [More Information]
  • Lambert, T. (2013). Improving patient adherence in schizophrenia and schizophrenia-related disorders. International Clinical Psychopharmacology, 28(Suppl1), S1-S2. [More Information]
  • Chen, R., Lambert, T. (2013). Managing cardiovascular risk factors in people with serious mental illness: the tragedy of neglect. Endocrinology Today: peer reviewed updates for medical practitioners, 2(1), 25-27.
  • Kalucy, M., Grunstein, R., Lambert, T., Glozier, N. (2013). Obstructive sleep apnoea and schizophrenia - A research agenda. Sleep Medicine Reviews, 17(5), 357-365. [More Information]
  • Lambert, T. (2013). Practical management of schizophrenia: the role of long-acting antipsychotics. International Clinical Psychopharmacology, 28(Suppl 1), S16-S27. [More Information]

2012

  • O'Connor, N., Mulley, R., Grasso, B., Lambert, T., Snars, J., Jhita, P. (2012). An Acute Recovery Unit: the first 18 months. Australasian Psychiatry, 20(3), 214-219. [More Information]
  • Robillard, R., Rogers, N., Whitwell, B., Lambert, T. (2012). Are Cardiometabolic and Endocrine Abnormalities Linked to Sleep Difficulties in Schizophrenia? A Hypothesis Driven Review. Clinical Psychopharmacology and Neuroscience, 10(1), 1-12.
  • Feiler, G., Chen, R., Pantelis, C., Lambert, T. (2012). Health behaviours of community-treated patients with psychosis. Australasian Psychiatry, 20(3), 208-213. [More Information]
  • Lambert, T., Emmerson, B., Hustig, H., Resseler, S., Jacobs, A., Butcher, B. (2012). Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. BMC Psychiatry, 12(1), 1-8. [More Information]
  • Robillard, R., Lambert, T., Rogers, N. (2012). Measuring sleep-wake patterns with physical activity and energy expenditure monitors. Biological Rhythm Research, 43(5), 555-562. [More Information]

2011

  • Happell, B., Platania-Phung, C., Gray, R., Hardy, S., Lambert, T., McAllister, M., Davies, C. (2011). A role for mental health nursing in the physical health care of consumers with severe mental illness. Journal of Psychiatric and Mental Health Nursing, 18(8), 706-711. [More Information]
  • Lambert, T., Olivares, J., Peuskens, J., DeSouza, C., Kozma, C., Otten, P., Crivera, C., Jacobs, A., Macfadden, W., Mao, L., et al (2011). Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Annals of General Psychiatry, 10(Article number 10), 1-7. [More Information]
  • Patel, M., Matonhodze, J., Baig, M., Gilleen, J., Boydell, J., Holloway, F., Taylor, D., Szmukler, G., Lambert, T., David, A. (2011). Increased use of antipsychotic long-acting injections with community treatment orders. Therapeutic Advances in Psychopharmacology, 1(2), 37-45. [More Information]
  • Lambert, T. (2011). Managing the metabolic adverse effects of antipsychotic drugs in patients with psychosis. Australian Prescriber, 34(4), 97-99.
  • Lambert, T., Taylor, D. (2011). Pharmacology of antipsychotic long-acting injections. In Peter Haddad, Tim Lambert, John Lauriello (Eds.), Antipsychotic Long-acting injections, (pp. 23-46). Oxford, United Kingdom: Oxford University Press.
  • Lambert, T. (2011). Prescribing patterns and determinants of use of antipsychotic long-acting injections: an international perspective. In Peter Haddad, Tim Lambert, John Lauriello (Eds.), Antipsychotic Long-acting injections, (pp. 209-239). Oxford, United Kingdom: Oxford University Press.
  • Dalton, A., Lambert, T., Schrover, R., Hertel, J., Kingsford Smith, D. (2011). The cost associated with administering risperidone long-acting injections in the Australian community. BMC Health Services Research, 11(236), 1-9. [More Information]
  • Haddad, P., Lambert, T., Lauriello, J. (2011). The role of antipsychotic long-acting injections in current practice. In Peter Haddad, Tim Lambert, John Lauriello (Eds.), Antipsychotic Long-acting injections, (pp. 241-260). Oxford, United Kingdom: Oxford University Press.
  • Kelin, K., Lambert, T., Brnabic, A., Newton, R., Ye, W., Escamilla, R., Chen, K., Don, L., Montgomery, W., Karagianis, J., et al (2011). Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence. Patient Preference and Adherence, 5, 213-222. [More Information]
  • McGorry, P., Cocks, J., Power, P., Burnett, P., Harrigan, S., Lambert, T. (2011). Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment. Schizophrenia Research and Treatment, 2011, 631690-1-631690-10. [More Information]

2010

  • Lambert, T. (2010). Disease Management: Multidimensional Approaches to Incomplete Recovery in Psychosis. In H Elkis, H Meltzer (Eds.), Therapy-Resistant Schizophrenia, (pp. 87-113). Basel: S. Karger AG.
  • Guastella, A., Einfeld, S., Gray, K., Rinehart, N., Tonge, B., Lambert, T., Hickie, I. (2010). Intranasal Oxytocin Improves Emotion Recognition in Youth with Autism Spectrum Disorders. Biological Psychiatry, 67, 692-694. [More Information]
  • Lambert, T. (2010). Office for Psychiatric Evaluation and New Media (open). In Edmond Chiu & Joy Preston (Eds.), The Department of Psychiatry at the University of Melbourne 1964-2009: Personal Reminiscences, (pp. 130-134). Melbourne: University of Melbourne.
  • Ryder, A., Lambert, T., Blaszczynski, A. (2010). The temporal stability and the determinants of subjective well being under antipsychotic medication in first-episode psychosis. Schizophrenia Research, 117(Special Issue), 402-402. [More Information]
  • Ryder, A., Lambert, T., Blaszczynski, A. (2010). The temporal stability and the determinants of subjective well-being under antipsychotic medication in first-episode psychosis. 2nd Schizophrenia International Research Society, .: Schizophrenia International Research Society.

2009

  • Lambert, T., Newcomer, J. (2009). Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care. Medical Journal of Australia, 190(4 Suppl), S39-S42. [More Information]
  • Lambert, T., Singh, B., Patel, M. (2009). Community treatment orders and antipsychotic long-acting injections. British Journal of Psychiatry, 195(52), S57-S62. [More Information]
  • Lambert, T., Addington, J., Burnett, P. (2009). Complete and incomplete recovery from first -episode psychosis. In Patrick D McGorry, Henry J Jackson (Eds.), The Recognition and Management of Early Psychosis: A Preventive Approach, (pp. 201-222). United Kingdom: Cambridge University Press.
  • Lambert, T. (2009). Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evidence-Based Mental Health, 12(2), 50. [More Information]
  • Lambert, T. (2009). The medical care of people with psychosis. Medical Journal of Australia, 190(4), 171-172. [More Information]

2008

  • Sundram, S., Lambert, T., Piskulic, D. (2008). Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia. Acta Psychiatrica Scandinavica, 117(6), 474-478. [More Information]
  • Lauriello, J., Lambert, T., Andersen, S., Lin, D., Taylor, C., McDonnell, D. (2008). An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia. Journal Of Clinical Psychiatry, 69(5), 790-799. [More Information]
  • Lambert, T. (2008). Drug delivery systems in schizophrenia. In Martin Lambert, Dieter Naber (Eds.), Current Schizophrenia, (pp. 12-18). London: Current Medicine Group Ltd.
  • Lambert, T., Norman, T. (2008). Ethnic differences in psychotropic drug response and pharmacokinetics. In Chee H. Ng, Keh-Ming Lin, Bruce S. Singh, Edmond Y. K. Chiu (Eds.), Ethno-psychopharmacology: Advances in Current Practice, (pp. 38-61). United States of America: Cambridge University Press.
  • Lambert, T., Detke, H., McDonnell, D., Lauriello, J., Anderson, S. (2008). Olanzapine long-acting injection: An 8-week double-blind, randomized, placebo-controlled study in acutely-ill patients with schizophrenia. International Journal of Neuropsychopharmacology, 11, 152-152.
  • Walter, G., DeLaroche, A., Soh, N., Hunt, G., Cleary, M., Malhi, G., Lambert, T., Correll, C., Rey, J. (2008). Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australasian Psychiatry, 16(4), 253-262. [More Information]

2007

  • Iqbal, N., Lambert, T., Masand, P. (2007). Akathisia: problem of history or concern of today. CNS Spectrums, 12(Suppl 14), 9-1-9-13. [More Information]
  • Elsom, S., Happell, B., Manias, E., Lambert, T. (2007). Expanded practice roles for community mental health nurses: a qualitative exploration of psychiatrists' views. Australasian Psychiatry, 15(4), 324-328. [More Information]
  • Subramaniam, M., Ng, C., Chong, S., Mahendran, R., Lambert, T., Pek, E., Huak, C. (2007). Metabolic differences between Asian and Caucasian patients on clozapine treatment. Human Psychopharmacology-Clinical and Experimental, 22(4), 217-222. [More Information]
  • Berk, M., Fitzsimons, J., Lambert, T., Pantelis, C., Kulkarni, J., Castle, D., Ryan, E., Jespersen, S., McGorry, P., Berger, G., et al (2007). Monitoring the Safe Use of Clozapine: A Consensus View from Victoria, Australia. CNS Drugs, 21(2), 117-127. [More Information]
  • Lambert, T. (2007). Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. Journal Of Clinical Psychiatry, 68(Suppl 6), 10-13. [More Information]
  • Weiden, P., Miller, A., Lambert, T., Buckley, P. (2007). The art and science of switching antipsychotic medications, part 2. Journal of Clinical Psychiatry, 68(1), e02. [More Information]

2006

  • Castle, D., Lambert, T., Melbourne, S., Cox, A., Boardman, G., Fairest, K., Davey, M., Goh, J., Kuluris, B., Berk, M. (2006). A clinical monitoring system for clozapine. Australasian Psychiatry, 14(2), 156-168. [More Information]
  • Lambert, T. (2006). Atypical antipsychotics in schizophrenia. Medicine Today, 7(1), 55-58.
  • Lambert, T. (2006). Selecting patients for long-acting novel antipsychotic therapy. Australasian Psychiatry, 14(1), 38-42. [More Information]

2005

  • Fitzsimons, J., Berk, M., Lambert, T., Bourin, M., Dodd, S. (2005). A review of clozapine safety. Expert Opinion on Drug Safety, 4(4), 731-744.
  • Ng, C., Chong, S., Lambert, T., Fan, A., Hackett, L., Mahendran, R., Subramaniam, M., Schweitzer, I. (2005). An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. International Clinical Psychopharmacology, 20(3), 163-168. [More Information]
  • Conley, R., Kelly, D., Lambert, T., Love, R. (2005). Comparison of Clozapine Use in Maryland and in Victoria, Australia. Psychiatric Services, 56(3), 320-323. [More Information]
  • McGorry, P., Killackey, E., Lambert, T., Lambert, M., Royal Australian and New Zealand College of Psychiatrists Clinical Practice, G. (2005). Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry, 39(1-2), 1-30. [More Information]

2004

  • Humberstone, V., Wheeler, A., Lambert, T. (2004). An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry, 38(4), 240-245.
  • Lambert, T., Chapman, L., Bell, J., Carr, N., D'Emden, M., Elsom, S., Groom, G., Henderson, S., Hickie, I., Hoffman, L., Meagher, J., et al (2004). Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Medical Journal of Australia, 181(10), 544-548.
  • Lambert, T., Kelly, D., Alcock, S., Conley, R. (2004). Letter To the Editor: Psychotropic Prescribing for Acute Inpatient Admissions in Patients with Severe Psychosis. Journal of Clinical Psychopharmacology, 24(1), 91-93.
  • Lambert, T. (2004). The value of psychiatric knowledge and expertise for general medical doctors. Emergency Psychiatry, 7, 35-38.

2003

  • Pantelis, C., Lambert, T. (2003). Managing patients with "treatment-resistant" schizophrenia. Medical Journal of Australia, 178(9 Supplement), S62-S66.
  • Lambert, T., Cock, N., Alcock, S., Kelly, D., Conley, R. (2003). Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacology-Clinical and Experimental, 18(5), 405-411. [More Information]
  • Lambert, T., Velakoulis, D., Pantelis, C. (2003). Medical comorbidity in schizophrenia. Medical Journal of Australia, 178(9 Supplement), S67-S70.
  • Gureje, O., Miles, W., Keks, N., Grainger, D., Lambert, T., McGrath, J., Tran, P., Catts, S., Fraser, A., Hustig, H., et al (2003). Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia Research, 61(2-3), 303-314.
  • Lambert, T., Brennan, A., Castle, D., Kelly, D., Conley, R. (2003). Perception of Depot Antipsychotics by Mental Health Professionals. Journal of Psychiatric Practice, 9(3), 252-260.
  • Lambert, T., Castle, D. (2003). Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia, 178(9 Supplement), S57-S61.
  • Lambert, M., Conus, P., Lambert, T., McGorry, P. (2003). Pharmacotherapy of first-episode psychosis. Expert Opinion on Pharmacotherapy, 4(5), 717-750.
  • McGorry, P., Killackey, E., Elkins, K., Lambert, M., Lambert, T. (2003). Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003). Australasian Psychiatry, 11(2), 136-147.

To update your profile click here. For support on your academic profile contact .